3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
3
Breast
2
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Glioblastoma
2
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Hemangioma, Cavernous, Central Nervous System
1
Colonic Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Filgrastim
12
Carboplatin
10
Paclitaxel
9
Peripheral Blood Stem Cell Transplantation
7
Cyclophosphamide
7
Ifosfamide
6
Temozolomide
5
Cisplatin
5
pembrolizumab
4
Nivolumab
4
Gemcitabine
4
Etoposide
4
Docetaxel
4
fludarabine
3
Thiotepa
3
Specimen Handling
3
Psychiatric Rehabilitation
3
Melphalan
3
Magnetic Resonance Spectroscopy
3
Immunologic Techniques
3
Fluorodeoxyglucose F18
3
Flow Cytometry
3
Bevacizumab
3
Amifostine
3
ulixertinib
2
trametinib
2
sargramostim
2
sapanisertib
2
pegfilgrastim
2
ixabepilone
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Atorvastatin
×
CNS
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn